X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs STRIDES PHARMA SCIENCE - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD STRIDES PHARMA SCIENCE MERCK LTD/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 45.3 52.2 86.9% View Chart
P/BV x 6.6 1.1 581.7% View Chart
Dividend Yield % 0.5 0.4 120.1%  

Financials

 MERCK LTD   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    MERCK LTD
Dec-17
STRIDES PHARMA SCIENCE
Mar-18
MERCK LTD/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,3581,147 118.4%   
Low Rs933642 145.3%   
Sales per share (Unadj.) Rs665.0317.2 209.6%  
Earnings per share (Unadj.) Rs56.67.8 721.2%  
Cash flow per share (Unadj.) Rs72.525.1 289.3%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %1.30.2 585.8%  
Book value per share (Unadj.) Rs441.7274.3 161.1%  
Shares outstanding (eoy) m16.6089.50 18.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.8 61.1%   
Avg P/E ratio x20.2114.0 17.8%  
P/CF ratio (eoy) x15.835.7 44.3%  
Price / Book Value ratio x2.63.3 79.5%  
Dividend payout %26.525.5 104.0%   
Avg Mkt Cap Rs m19,01180,058 23.7%   
No. of employees `0001.52.5 61.6%   
Total wages/salary Rs m1,6964,341 39.1%   
Avg. sales/employee Rs Th7,150.011,325.8 63.1%   
Avg. wages/employee Rs Th1,098.71,731.4 63.5%   
Avg. net profit/employee Rs Th608.2280.1 217.2%   
INCOME DATA
Net Sales Rs m11,04028,394 38.9%  
Other income Rs m240941 25.5%   
Total revenues Rs m11,27929,334 38.5%   
Gross profit Rs m1,3763,965 34.7%  
Depreciation Rs m2641,540 17.1%   
Interest Rs m01,962 0.0%   
Profit before tax Rs m1,3521,403 96.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m170-436 -39.0%   
Tax Rs m58397 599.0%   
Profit after tax Rs m939702 133.8%  
Gross profit margin %12.514.0 89.3%  
Effective tax rate %43.16.9 621.7%   
Net profit margin %8.52.5 344.0%  
BALANCE SHEET DATA
Current assets Rs m7,52324,836 30.3%   
Current liabilities Rs m2,25318,993 11.9%   
Net working cap to sales %47.720.6 232.0%  
Current ratio x3.31.3 255.4%  
Inventory Days Days5271 73.5%  
Debtors Days Days41113 35.8%  
Net fixed assets Rs m1,24034,289 3.6%   
Share capital Rs m166895 18.5%   
"Free" reserves Rs m7,16723,651 30.3%   
Net worth Rs m7,33324,546 29.9%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m9,91265,437 15.1%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.10.4 256.7%   
Return on assets %9.54.1 232.7%  
Return on equity %12.82.9 447.7%  
Return on capital %20.86.9 301.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01515,697 6.5%   
Fx outflow Rs m3,043735 413.7%   
Net fx Rs m-2,02814,962 -13.6%   
CASH FLOW
From Operations Rs m5371,871 28.7%  
From Investments Rs m-4765,826 -8.2%  
From Financial Activity Rs m-220-10,157 2.2%  
Net Cashflow Rs m-160-2,615 6.1%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 37.8 48.1%  
FIIs % 1.0 8.6 11.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 25.9 112.4%  
Shareholders   28,591 56,241 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare MERCK LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Dec 17, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - DR. REDDYS LAB COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS